AzTrials
AzTrials

HypertensionNCT02600338

Meta-analyses of the Effect of Legumes on Blood Pressure

An observational study of Hypertension and Cardiovascular Disease, run by John Sievenpiper at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Legumes are generally recognized as healthy dietary components, and although beans and legumes are recommended in food guidelines in North America, guidelines vary in regards to how much and how often these foods should be consumed. Read more about this study

Who is it for?
Any age
Conditions the study is for
Hypertension, Cardiovascular Disease, Dyslipidemia
What is being tested?
Legumes
How many people
1 participants
Where
1 siteCanada
Study dates
Sep 2014to Sep 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Varied

Who may be able to join

  • Dietary trials in humans
  • Legumes comprising majority of intervention.
  • Randomized treatment allocation >=3-weeks
  • Suitable control (i.e. exchange of other dietary components for legumes)
  • viable endpoint data

Who cannot join

  • Non-human studies
  • Legumes not majority of intervention, or intervention mainly involves an isolated component of legumes (ex. oil or protein isolate)
  • Nonrandomized treatment allocation <3-weeks
  • Lack of a suitable control
  • no viable endpoint data

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Toronto 3-D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital

    Toronto, Ontario, M5C 2T2

Other trials in Canada

About this study

Official title: Effect of Legumes on Blood Pressure in Humans: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Legumes are generally recognized as healthy dietary components, and although beans and legumes are recommended in food guidelines in North America, guidelines vary in regards to how much and how often these foods should be consumed. Furthermore, although North American and European guidelines recommend dietary pulses for glycemic control, dietary pulses and other legumes are not specifically suggested for controlling blood pressure and maintaining heart health. To improve evidence-based guidance for legume recommendations, the investigators propose to conduct a systematic review of clinical studies to assess the effect of eating legumes in exchange for other foods on blood pressure in humans. The systematic review process allows the combining of the results from many small studies in order to arrive at a pooled estimate, similar to a weighted average, of the true effect. The investigators will be able to explore whether eating legumes has different effects in different demographics, and whether or not the effect of legumes depends on how much/often they are eaten. The findings of this proposed knowledge synthesis will help improve the health of Canadians through informing recommendations for the general public, as well as those at risk of heart disease and diabetes.

Read the detailed description

Background: Legumes (e.g. chick peas, beans, lentils, peas, soy, peanuts, lupins) are a source of slowly digestible carbohydrate, vegetable protein, fibre, and potassium. Canada's Food Guide encourages consumption of legumes such as beans, lentils, and tofu "often" as meat alternatives, and the dietary guidelines for Americans include beans, peas, and soy products as "foods to increase", and as possible components of a healthy eating pattern. While the European (EASD), Canadian (CDA), and American (ADA) Diabetes Associations recommend the consumption of dietary pulses as a means of improving diabetes control, and the American Heart Association (AHA) recommends the consumption of a healthy eating pattern which includes legumes for cardiovascular health, consolidated evidence for the specific recommendation of legumes for heart health is lacking.

Need for a review: The lack of data to support health claims and other cardiometabolic recommendations represent an urgent call for stronger evidence. A systematic review and meta-analysis of controlled feeding trials remains the "Gold Standard" of evidence for nutrition guidelines development.

Objectives: To provide evidence-based guidance for public health policy, health claims, and nutrition guidelines relating to legumes, the investigators will conduct a systematic review and meta-analysis (knowledge synthesis) of randomized controlled feeding trials to assess the effect of legumes on blood pressure.

Design: The planning and conduct of the proposed meta-analyses will follow the Cochrane handbook for systematic reviews of interventions. The reporting will follow the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.

Data sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials will be searched using appropriate search terms.

Study selection: Intervention trials that investigate diets high in legumes compared with control diets not-containing legumes on blood pressure outcomes in humans will be included. Studies that are <3-wks duration or lack a control will be excluded.

Data extraction: Independent reviewers (≥2) will extract information about study design, sample size, subject characteristics, type and form of legume, dose, follow-up, and the composition of the background diets. Mean±SEM values will be extracted for all outcomes. Standard computations and imputations will be used to derive missing variance data.

Outcomes: The proposed analysis will assess blood pressure control, looking at systolic, diastolic, and mean arterial blood pressure. Where data for both change-from-baseline differences and end differences are equally available, the investigators will use the difference in change from baseline as the primary end point for analyses.

Data synthesis: Pooled analyses stratified by underlying disease status will be conducted for each area of metabolic control using the Generic Inverse Variance method with fixed or random effects models, depending on the number of relevant studies obtained. Random-effects models will be used in the case of collection of 5 or more studies, even in the absence of statistically significant between-study heterogeneity, as they yield more conservative summary effect estimates in the presence of residual heterogeneity. Paired analyses will be applied to all crossover trials. Heterogeneity will be tested by the Cochran Q statistic and quantified by the I2-statistic. Sources of heterogeneity will be explored by sensitivity and subgroup analyses. A priori subgroup analyses will include legume type, legume dose, duration of follow-up, sodium intake (absolute level, within-treatment change, and between-treatment change), dietary fibre intake (absolute level, within-treatment change, and between-treatment change), design (crossover, parallel), study quality, and baseline endpoint values. Significant unexplained heterogeneity will be investigated by additional post hoc subgroup analyses. Meta-regression analyses will assess the significance of subgroups analyses. When >=10 studies are available, publication bias will be investigated by inspection of funnel plots and formal testing using the Egger test and the Begg test. If publication bias is suspected, then the investigators will attempt to adjust for funnel plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill method.

Evidence Assessment: The strength of the evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).

Knowledge translation plan: Results will be disseminated through traditional means such as interactive presentations at local, national, and international scientific meetings and publication in high impact factor journals. Target adopters will include the clinical practice, public health, industry, research communities, and patient groups. Feedback will be incorporated and used to guide areas for future research.

Preliminary findings: The investigators previously conducted a systematic review and meta-analysis of the effect of dietary pulses (a subset of legumes - does not include leguminous oil-seeds) on glycemic control in 41 controlled feeding trials. It was found that pulses alone or as part of low-glycemic index or high-fibre diets improved markers of glycemic control. The investigators also previously conducted a systematic review and meta-analysis of the effect of dietary pulses on blood pressure in 8 isocaloric controlled feeding trials. It was found that diets high in dietary pulses significantly lowered systolic and mean arterial blood pressure compared with diets not containing pulses.

Significance: The proposed project will aid in knowledge translation related to the effects of legumes on blood pressure, updating our knowledge synthesis on dietary pulses and broadening it to assess the effect of all types of legumes, and strengthening the evidence-base for dietary recommendations and health claims and improving heart health outcomes through informing healthcare providers and patients, stimulating industry innovation, and guiding future research.

Being tested
Legumes
Keywords
Systematic review and meta-analysis, Evidence-based medicine (EBM), Evidence-based nutrition (EBN), Clinical practice guidelines, Clinical trials, Legumes, Beans, peas, chickpeas, lentils, soy, peanuts, lupins, Cardiometabolic risk factors, Blood pressure
Medical subject headings
Hypertension, Cardiovascular Diseases, Dyslipidemias, Diabetes Mellitus, Metabolic Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LegumesOther

    beans, peas, chickpeas, lentils, soybeans, lupins, peanuts in whole or flour form

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Systolic blood pressure

    Measured: Up to 2-years

  2. Diastolic blood pressure

    Measured: Up to 2-years

  3. Mean arterial pressure

    Measured: Up to 2-years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Nov 2015 (estimated)
  2. Study startSep 2014
  3. Primary completionSep 2016 (estimated)
  4. Study completionSep 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Enrolment
1 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02600338
Sponsor's protocol ID
Legumes & BP 2014
Status last verified
Nov 2015
First submitted
30 Oct 2015
Last updated
9 Nov 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Hypertension and Cardiovascular Disease, run by John Sievenpiper at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Systolic blood pressure (time frame: Up to 2-years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in